Elevate your local knowledge
Sign up for the iNFOnews newsletter today!
BERLIN – Swiss drug maker Novartis AG has reported a fourth-quarter net profit of $2.08 billion.
The result is 72 per cent higher than the $1.21 billion net profit reported for the last quarter of 2011 when the Basel-based company took a $900-million after ending its clinical study into wider uses of the hypertension drug Tekturna.
Novartis said Wednesday that fourth-quarter sales in 2012 were almost flat at $14.83 billion compared with $14.78 billion in the same period the previous year.
The company also said that long-time chairman and former chief executive Daniel Vasella will leave the board at the next shareholders’ meeting at the end of February.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Want to share your thoughts, add context, or connect with others in your community?
You must be logged in to post a comment.